DOI: 10.1002/ame2.12355
Expression and prognosis of inducible T-cell co-stimulator and its ligand in Chinese stage Ⅰ-Ⅲ lung adenocarcinoma patients
Xiao-Kai Zhan1
Xi-Kun Liu2
Sen Zhang2
Hong Chen3
1.Division of Oncology and Hematology,Beijing Chao-Yang Hospital,Capital Medical University,Beijing,P.R.China2.State Key Laboratory of Bioactive Substances and Functions of Natural Medicines,Institute of Materia Medica,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,P.R.China3.Pathology Department,Beijing Chao-Yang Hospital,Capital Medical University,Beijing,P.R.China
摘要：Background:Immunotherapy has become the fastest-adopting treatment paradigm for lung cancer with improved survival.By binding with its ligand(inducible T-cell co-stimulator and its ligand[ICOSL]),an inducible T-cell co-stimulator(ICOS)could con-tribute to reversing immunosuppression and improving immune response and thus be a potential target for cancer immunotherapy.
Methods:We selected 54 formalin-fixed,paraffin-embedded tumor tissues from cases with stage Ⅰ-Ⅲ lung adenocarcinoma cancer.Immunohistochemical expression of ICOS and ICOSL was evaluated.The correlation with clinical parameters in Chinese patients was also compared with TCGA results.
Results:The positive rates of ICOS and ICOSL were 68%and 81.5%,respectively,in lung tumor tissues.Of these,9 cases had a low expression of ICOS,and 22 cases had a high expression of ICOS;ICOSL expression was low in 20 cases and high in 24 cases.According to the International Association for the Study of Lung Cancer(8th edition),phase I lesions were detected in 21 cases,phase Ⅱ lesions in 15 cases,and phase Ⅲ lesions in 18 cases.The median survival time of all patients was 44.5 months,and the median disease-free survival was 32 months.Univariate analysis showed that the factors significantly associated with overall survival were tumor size,regional lymph node involvement,stage,and expression level of ICOS/ICOSL.Survival analysis using log-rank test indicated that the lower ICOS+ cell infiltration may predict poor prog-nosis,whereas lower ICOSL protein expression may be associated with better prog-nosis,but ICOSL data need further validation in larger samples due to inconsistency in TCGA Mrna prediction.
Conclusion:ICOS/ICOSL might be associated with prognosis of lung cancer,and ICOS and its ligand may be potential therapeutic targets in non-small cell lung cancer.
机标关键词：expressionchineseprognosisligandstageadenocarcinomaco-stimulatorinducible
论文发表日期：2023-10-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：10( 464-473 )
英文信息